Elekta AB (publ) (EKTAY) Expected to Announce Quarterly Earnings on Thursday

Posted by Wayne Rhoads on Mar 5th, 2025

Elekta AB (publ) (OTCMKTS:EKTAY – Get Free Report) is projected to issue its quarterly earnings data on Thursday, March 6th. Analysts expect the company to announce earnings of $0.09 per share and revenue of $444.70 million for the quarter.

Elekta AB (publ) (OTCMKTS:EKTAY – Get Free Report) last released its earnings results on Friday, February 21st. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). Elekta AB (publ) had a net margin of 5.65% and a return on equity of 11.07%. The company had revenue of $416.86 million during the quarter, compared to analysts’ expectations of $435.89 million. On average, analysts expect Elekta AB (publ) to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Elekta AB (publ) Price Performance

Elekta AB (publ) stock opened at $5.75 on Wednesday. Elekta AB has a 1 year low of $5.25 and a 1 year high of $8.24. The firm has a 50 day moving average price of $5.72 and a 200 day moving average price of $6.06. The company has a market cap of $2.21 billion, a price-to-earnings ratio of 23.00 and a beta of 1.22. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.81 and a current ratio of 1.05.

Elekta AB (publ) Cuts Dividend

The firm also recently declared a dividend, which will be paid on Thursday, March 27th. Shareholders of record on Friday, March 7th will be given a dividend of $0.1072 per share. The ex-dividend date is Friday, March 7th. Elekta AB (publ)’s dividend payout ratio (DPR) is 40.00%.

Analyst Upgrades and Downgrades

Separately, Sanford C. Bernstein raised shares of Elekta AB (publ) from a “strong sell” rating to a “hold” rating in a research report on Wednesday, January 29th.

Get Our Latest Research Report on Elekta AB (publ)

About Elekta AB (publ)

(Get Free Report)

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.